Pacific Biosciences Of California (PACB) Total Liabilities (2010 - 2026)

Pacific Biosciences Of California has reported Total Liabilities for 17 years, with the latest figure at $785.1 million in Q2 2026.

• On a quarterly basis, Total Liabilities rose 2.76% year-over-year to $785.1 million in Q2 2026; TTM through Jun 2026 was $785.1 million, a 2.76% increase from a year earlier, with the FY2025 full-year figure at $778.7 million, up 3.3% from the prior year.
• Total Liabilities was $785.1 million for Q2 2026 at Pacific Biosciences Of California, up from $780.0 million in the prior quarter.
• The five-year high for Total Liabilities was $1.2 billion in Q2 2023, with the low at $753.9 million in Q4 2024.
• Average Total Liabilities over 5 years is $989.7 million, with a median of $1.0 billion recorded in 2024.
• The sharpest annual moves came in 2022 and 2024: Total Liabilities climbed 23.63% in 2022, then fell 27.84% in 2024.
• Over 5 years, Total Liabilities stood at $1.2 billion in 2022, then slipped by 13.24% to $1.0 billion in 2023, then dropped by 27.84% to $753.9 million in 2024, then climbed by 3.3% to $778.7 million in 2025, then climbed by 0.81% to $785.1 million in 2026.
• The last three Total Liabilities figures came in at $785.1 million (Q2 2026), $780.0 million (Q1 2026), and $778.7 million (Q4 2025), per Business Quant data.